Marc Lerchenmueller

Prof. Dr. Marc Lerchenmüller holds the assistant professorship of Technological Innovation and Management Science at the University of Mannheim. He is also a Research Fellow at the Yale School of Management. His research pertains to the economics of innovation and entrepreneurship. In particular, he examines how individuals’ and organizations’ strategic adaptation to competitive conditions influences the pathway to innovation. His second stream of research concerns technology transfer and science policy. His research appears in management journals and medical journals, like the BMJ and Circulation, and has been featured in Nature and popular media like the Wall Street Journal and the New York Times.

Prior to his academic career, Prof. Lerchenmüller worked for the Boston Consulting Group in New York City. He also served on the four-person founding team of InoCard GmbH, a biotechnology start-up that was sold to uniQure N.V. and then entered into a development alliance with Bristol-Myers Squibb. Prof. Lerchenmüller is also a co-founder of AaviGen GmbH, a biotechnology start-up focused on gene therapies in cardiovascular disease indications. Prof. Lerchenmüller earned his doctorate at WHU and holds Master degrees in Public Health with a focus on regulatory affairs from Yale University and in Financial Economics from the University of Oxford.

Education

• Master's Degree Yale University (2011 — 2013)
• Doctor rer. pol. WHU – Otto Beisheim School of Management (2010 — 2013)
• Master's Degree University of Oxford (2006 — 2007)
• Bachelor's Degree Imperial College London (2004 — 2006)
• University of Oxford

Companies

• Co-Founder, Managing Director, CFO AaviGen GmbH (2019)
• Assistant Professor University of Mannheim, Business School - Fakultät BWL (2019)
• Research Fellow Yale School of Management (2014)
• Owner Glas Lerchenmüller GmbH (2007)
• Senior Consultant The Boston Consulting Group (2007 — 2014)
• Co-Founder InoCard GmbH (2011 — 2014)

Skills

• Strategy